

## References

I-28

1. MacDermott R, Lichenstein G. Infliximab in Crohn's disease. *UpToDate*. Accessed July 19, 2013.
2. Lichenstein G. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. *Therap Adv Gastroenterol*. 2013;6(4):269-293.
3. Ringold S, Weiss P, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. 2013;65(10):2499-2512.
4. Sanchez-Cano D, Callejas-Rubio J, Ruiz-Villaverde R, et al. Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's Disease, sarcoidosis, and noninfectious uveitis. *Mediators Inflamm*. 2013;2013:286857.
5. McErlane F, Foster H, Davies R, et al. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford)*. 2013;52(10):1905-1913.
6. Pasadhika S, Rosenbaum J. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. *Biologics*. 2014;8:67-81.
7. Park KT, Sin A, Wu M, et al. Utilization Trends of Anti-TNF Agents and Health Outcomes in Adults and Children with Inflammatory Bowel Diseases: A Single-center Experience. *Inflamm Bowel Dis*. 2014;20(7):1242-1249.
8. Levy-Clarke G, Jabs D, Read R, et al. Expert panel recommendations for the use of anti-tumor necrosis Factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology*. 2014;121(3):785-796.
9. Semeraro F, Arcidiacono B, Nascimbeni G, et al. Anti-TNF therapy for Juvenile Idiopathic Arthritis (JIA) - related uveitis. *Drug Des Devel Ther*. 2014;8:341-348.
10. He Y, Jia SB, Zhang W, et al. New options for uveitis treatment. *Int J Ophthalmol*. 2013;6(5):702-707.
11. Beukelman T, Ringold S, Davis T, et al. Disease Modifying anti-rheumatic drug use in the treatment of Juvenile Idiopathic Arthritis: A cross-sectional analysis of the CARRA Registry. *JRheumatol*. 2012;39(9):1867-1874.
12. Merida S, Palacios E, Navea A, Bosch-Morell F. New immunosuppressive therapies in uveitis treatment. *Int J Mol Sci*. 2015;16(8):18778-18795.
13. American Gastroenterological Association. (AGA) Use of thiopurines, methotrexate and anti-TNF alpha biologic agents for the induction and maintenance of remission in inflammatory Crohn's Disease. Accessed February 16, 2016.
14. Bradley G, Oliva-Hemker M. Pediatric ulcerative colitis: current treatment approaches including role of infliximab. *Biologics*. 2012;6:125-134.
15. Rowe W. Inflammatory bowel disease treatment & management. *Medscape Updated*: January 2015. Accessed May 20, 2016.
16. Blair H A, Deeks E D. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. *BioDrugs*. 2016;469-480.

17. Takeuchi T, Yamanaka H, Tanaka Y, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. *Modern Rheumatology*. 2015;817-824.
27. Yoo D H, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Ann Rheum Dis*. 2013;1-8.
28. Judson M A, Baughman R P, Costabel U, Mack M, Barnathan E S. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: A retrospective analysis from a randomized clinical trial. *Resp. Medicine*. 2014;189-194.
29. Baughman R P, Lower E E. Treatment of Sarcoidosis. *Clinic Rev Allerg Immunol*. 2015;79–92.
30. Thomson Micromedex DrugDex Compendium®. Infliximab, cA2 (Remicade) 2017.
31. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Infliximab (Remicade). Accessed March 10, 2017.
32. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Infliximab (Inflectra). Accessed March 10, 2017.
33. Remicade® (Infliximab, cA2) [package insert]. Horsham, PA. Jansen Biotech: 10/2013, revised 01/2015.
34. INFLECTRA (infliximab-dyyb) [package insert]. Lake Forest, IL. Jansen Pfizer Company: 04/2016.
35. RENFLEXIS (infliximab-abda) [package insert]. Kenilworth, NJ. Merck Sharp & Dohme Corp.: 04/2017.
36. [Condino AA, Fidanza S, Hoffenburg EJ. A home infliximab infusion program. \*NHS\*. 2005;67-69.](#)
37. [Barfield E, Solomon A, Sockolow R. Infliximab in the Home – Does it Affect the Health-Related Quality of Life of Pediatric Patients with Inflammatory Bowel Disease? \*Practical Gastro\*. 2016;16-23.](#)
38. [ASHP Guidelines on Home Infusion Pharmacy Services, 2013.](#)